Kyowa Kirin, a Tokyo-based bio/pharmaceutical company, is investing $530 million to build a new biomanufacturing facility in Sanford, North Carolina. Construction of the 15,951-square-meter, two-bioreactor facility is scheduled to break ground in the third quarter of 2024.  

The facility will manufacture biologic therapies, including antibodies, for Kyowa Kirin’s planned clinical trials and future commercial use. Additional land will allow for future expansion, should the company’s portfolio necessitate greater capacity as its pipeline programs advance. 

The Sanford facility will round out Kyowa Kirin’s global manufacturing network, which includes sites in Takasaki City, Gunma Prefecture, and Ube City, Yamaguchi Prefecture in Japan.  

Source: Kyowa Kirin